Loading quotes...
Forecast
The analysts' average price target is €27.15 (+412.26%). The median is €6.27 (+18.30%).
| Buy |
9 |
| Hold |
19 |
| Sell |
4 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 392.59M | 2.07% |
| Gross profit | 259.02M | 1.28% |
| Net profit | -109.02M | 30.69% |
| EBITDA | -120.24M | 69.74% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €200.66M |
Number of shares | 38.37M |
52-week high/low | €11.91 - €2.83 |
| Dividends | No |
Beta | 0.82 |
P/E ratio | -1.91 |
PEG ratio | 0.04 |
P/B ratio | 0.94 |
P/S ratio | 0.55 |
Company profile
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Name | Nevro Corp. |
| CEO | Kevin R. Thornal |
| Headquarters | Redwood City,
ca USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 11/06/2014 |
| Employees | 1,099 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | NVRO |
Frankfurt | 1N7.F |
Düsseldorf | 1N7.DU |
SIX | 1N7.SW |
